Clinical trial · Observational
Early Detection of Epstein-Barr Virus Related Disease.
Early Detection of Epstein-Barr Virus Related Disease. Improving Quantification of EBV in Blood Samples Using Polymerase Chain Reaction.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Epstein-Barr virus (EBV) is one of several herpesviruses that cause disease in humans. EBV virus has an oncogenic potential, and it has been associated with the development of a wide range of cancers. Previous studies have shown a close association between EBV and Post-Transplant Lymphoproliferative disorder (PTLD) in transplant recipients. As part of a preventive approach against PTLD, several transplantation units now monitor the occurrence of EBV-DNAemia after transplantation. However, there is little evidence to guide this strategy; nor is there consensus concerning either the best specimen to use for EBV analysis (whole blood or plasma). In this study investigators aim to optimise and validate a polymerase chain reaction (PCR)-test for EBV-DNA on, respectively, whole blood, plasma and a combination of plasma and lymphocytes. The investigators wish to determine which of the three tests best predicts current and future risk of development of EBV-related diseases such as mononucleosis and PTLD.
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epstein-Barr Viraemia | — | UNRESOLVED | — |
| Epstein-Barr Virus Infections | — | UNRESOLVED | — |
| Epstein-Barr Virus-Related Hodgkin Lymphoma | EBV-Related Hodgkin Lymphoma | ALIAS | 0.90 |
| Epstein-Barr Virus Related Malignancy | EBV-Related Malignant Neoplasm | ALIAS | 0.90 |
| Epstein-Barr Virus-Related Non-Hodgkin Lymphoma | EBV-Related Non-Hodgkin Lymphoma | ALIAS | 0.90 |
| Hemophagocytic Lymphohistiocytoses | — | UNRESOLVED | — |
| Hemophagocytosis | — | UNRESOLVED | — |
| Mononucleosis | — | UNRESOLVED |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Department of Kidney Medicine
- description
- Primarily transplant recipients undergoing monitoring for EBV and patients suspected for having PTLD.
- label
- Department of Hematology
- description
- Patients diagnosed with PTLD and other kinds of lymphoma. Patients undergoing hematopoietic stem cell transplantation and patients with hemophagocytosis.
- label
- Department of pediatrics
- description
- Children undergoing transplantation. Children diagnosed with hemophagocytic lymphohistiocytosis.
Primary outcomes (2)
- measure
- Incidence of proven EBV disease
- timeFrame
- From time of blood sampling up to 24 months.
- description
- Symptoms compatible with EBV disease combined with a tissue biopsy positive for EBV
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients suspected for having EBV disease. Exclusion Criteria: * If the patients has any contraindications for blood sampling.
References
Publications (1)
- RESULTLudvigsen LUP, Andersen AS, Hamilton-Dutoit S, Jensen-Fangel S, Bottger P, Handberg KJ, Ivarsen P, d'Amore F, Bibby BM, Albertsen BK, Jespersen B, Thomsen MK. A prospective evaluation of the diagnostic potential of EBV-DNA in plasma and whole blood. J Clin Virol. 2023 Oct;167:105579. doi: 10.1016/j.jcv.2023.105579. Epub 2023 Aug 30. PMID 37683299